{"id":"lisaftoclax-apg-2575","safety":{"commonSideEffects":[{"rate":null,"effect":"Tumor lysis syndrome"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lisaftoclax (APG-2575) is a selective inhibitor of BCL-2 and BCL-xL, anti-apoptotic proteins that allow cancer cells to evade programmed cell death. By blocking these proteins, the drug restores the intrinsic apoptotic pathway, forcing cancer cells to undergo apoptosis. This mechanism is particularly relevant in hematologic malignancies where BCL-2 overexpression drives survival.","oneSentence":"Lisaftoclax is a BCL-2 family protein inhibitor that promotes apoptosis by blocking anti-apoptotic proteins in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:08.192Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Small lymphocytic lymphoma (SLL)"},{"name":"Acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT05147467","phase":"PHASE2","title":"Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-12-28","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":75},{"nctId":"NCT07459608","phase":"PHASE2","title":"Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-03-10","conditions":"Indolent Lymphoma, WM, MZL","enrollment":75},{"nctId":"NCT06182969","phase":"PHASE1, PHASE2","title":"A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2024-08-09","conditions":"SLE","enrollment":40},{"nctId":"NCT07272499","phase":"PHASE2","title":"Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-09-10","conditions":"Mantle Cell Lymphoma (MCL)","enrollment":25},{"nctId":"NCT06389292","phase":"PHASE3","title":"A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2024-06-11","conditions":"Acute Myeloid Leukemia","enrollment":486},{"nctId":"NCT06641414","phase":"PHASE3","title":"Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2025-01-22","conditions":"Higher-risk Myelodysplastic Syndrome","enrollment":490},{"nctId":"NCT04496349","phase":"PHASE2","title":"A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-07-12","conditions":"T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma","enrollment":78},{"nctId":"NCT04501120","phase":"PHASE1, PHASE2","title":"Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2020-09-28","conditions":"Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy","enrollment":458},{"nctId":"NCT06104566","phase":"PHASE3","title":"Global Trial in APG2575 for Patients With CLL/SLL","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2023-12-20","conditions":"CLL/SLL","enrollment":400},{"nctId":"NCT07159906","phase":"PHASE1, PHASE2","title":"Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-08","conditions":"Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma","enrollment":62},{"nctId":"NCT04260217","phase":"PHASE1","title":"APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia","status":"COMPLETED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-05-30","conditions":"Waldenstrom Macroglobulinemia","enrollment":46},{"nctId":"NCT04494503","phase":"PHASE1, PHASE2","title":"Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2020-08-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":123},{"nctId":"NCT03913949","phase":"PHASE1","title":"A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-06-03","conditions":"Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma","enrollment":74},{"nctId":"NCT04215809","phase":"PHASE1","title":"Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2020-03-02","conditions":"CLL/SLL","enrollment":144},{"nctId":"NCT05701306","phase":"PHASE1","title":"APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2023-02-28","conditions":"Neuroblastoma, Solid Tumor","enrollment":100},{"nctId":"NCT04946864","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer","status":"SUSPENDED","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-08-13","conditions":"Breast Cancer, Solid Tumor, Adult","enrollment":65},{"nctId":"NCT03537482","phase":"EARLY_PHASE1","title":"APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2018-08-07","conditions":"Hematologic Malignancies","enrollment":90},{"nctId":"NCT06319456","phase":"PHASE3","title":"A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.","status":"RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2024-04-07","conditions":"CLL/SLL","enrollment":344},{"nctId":"NCT04964518","phase":"PHASE1, PHASE2","title":"A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)","status":"UNKNOWN","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-07-30","conditions":"AML, Adult","enrollment":24},{"nctId":"NCT04942067","phase":"PHASE1, PHASE2","title":"APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-12-23","conditions":"Multiple Myeloma, Amyloidosis","enrollment":108},{"nctId":"NCT04674514","phase":"PHASE1, PHASE2","title":"APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"Ascentage Pharma Group Inc.","startDate":"2021-04-13","conditions":"Multiple Myeloma","enrollment":48},{"nctId":"NCT05495035","phase":"PHASE1","title":"Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-09-01","conditions":"Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Induction phase","Maintenance phase"],"phase":"phase_3","status":"active","brandName":"Lisaftoclax (APG-2575)","genericName":"Lisaftoclax (APG-2575)","companyName":"Ascentage Pharma Group Inc.","companyId":"ascentage-pharma-group-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lisaftoclax is a BCL-2 family protein inhibitor that promotes apoptosis by blocking anti-apoptotic proteins in cancer cells. Used for Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), Acute myeloid leukemia (AML).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}